

Alessandra Fabi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2758082/alessandra-fabi-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

139
papers

3,055
citations

31
h-index

48
g-index

146
ext. papers

3,531
ext. citations

4.9
avg, IF

4.58
L-index

#	Paper	IF	Citations
139	T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer. <i>Cancers</i> , 2022 , 14, 2468	6.6	0
138	Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. <i>Molecular Cancer</i> , 2021 , 20, 151	42.1	1
137	Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. <i>Cancers</i> , 2021 , 13,	6.6	1
136	Use of rehabilitation pathways in women with breast cancer in the first 12 months of the disease: a retrospective study. <i>BMC Cancer</i> , 2021 , 21, 311	4.8	2
135	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021 , 27, 3443-3455 ²	12.9	5
134	Neoadjuvant Chemotherapy in Breast Cancer: An Advanced Personalized Multidisciplinary Prehabilitation Model (APMP-M) to Optimize Outcomes. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1
133	Oligometastatic Breast Cancer: How to Manage It?. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	2
132	Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9). <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 103-109	4.4	0
131	Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial. <i>Future Oncology</i> , 2021 , 17, 3445-3456	3.6	1
130	The Experience of Oncology Healthcare Providers in the Central Italy during the COVID-19 Lockdown. <i>Cancers</i> , 2020 , 12,	6.6	2
129	p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study. <i>Clinical Breast Cancer</i> , 2020 , 20, e761-e770	3	3
128	Nanoparticle albumin-bound paclitaxel/liposomal-encapsulated doxorubicin in HER2-negative metastatic breast cancer patients. <i>Future Oncology</i> , 2020 , 16, 1629-1637	3.6	2
127	Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. <i>Journal of Neurosurgical Sciences</i> , 2020 , 64, 313-334	1.3	11
126	T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. <i>Clinical Breast Cancer</i> , 2020 , 20, e181-e187	3	24
125	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020 , 15, 20-27	2.4	
124	Comorbidities in elderly patients with glioblastoma: a field-practice study. <i>Future Oncology</i> , 2019 , 15, 841-850	3.6	4
123	Open Kyphoplasty for Metastatic Spine Disease: A Retrospective Clinical Series. <i>World Neurosurgery</i> , 2019 , 127, e751-e760	2.1	5

122	Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO). <i>Supportive Care in Cancer</i> , 2019 , 27, 1041-1047	3.9	11
121	Phase II study of weekly carboplatin in pretreated adult malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2019 , 144, 211-216	4.8	1
120	Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. <i>Cancers</i> , 2019 , 11,	6.6	26
119	RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 12	12.8	66
118	Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis. <i>International Journal of Neuroscience</i> , 2019 , 129, 593-597	2	18
117	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 474-485	21.7	39
116	Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. <i>Breast</i> , 2018 , 38, 86-91	3.6	20
115	A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma. <i>Journal of Neuro-Oncology</i> , 2018 , 138, 527-535	4.8	7
114	Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?. <i>Oncology</i> , 2018 , 94 Suppl 1, 29-33	3.6	5
113	T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer. <i>Breast</i> , 2018 , 41, 137-143	3.6	26
112	Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018 , 37, 47	12.8	38
111	Kyphoplasty with purified silicone VK100 (Elastoplasty) to treat spinal lytic lesions in cancer patients: A retrospective evaluation of 41 cases. <i>Clinical Neurology and Neurosurgery</i> , 2018 , 171, 184-189 ²		5
110	Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥65 years: new lessons for clinical practice from the EVA study. <i>Oncotarget</i> , 2018 , 9, 31877-31887	3.3	2
109	Dual-time 18F-FDG PET/CT for the detection of liver metastases in breast cancer. <i>Nuclear Medicine Communications</i> , 2018 , 39, 1183-1189	1.6	7
108	Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 1272-1275	2.7	2
107	Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis. <i>In Vivo</i> , 2018 , 32, 839-842	2.3	0
106	Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study. <i>Breast Cancer Research</i> , 2017 , 19, 46	8.3	19
105	The course of cancer related fatigue up to ten years in early breast cancer patients: What impact in clinical practice?. <i>Breast</i> , 2017 , 34, 44-52	3.6	44

104	Zonisamide in Brain Tumor-Related Epilepsy: An Observational Pilot Study. <i>Clinical Neuropharmacology</i> , 2017 , 40, 113-119	1.4	7
103	Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. <i>Epilepsy and Behavior</i> , 2017 , 73, 83-89	3.2	29
102	Prognostic impact of proliferation for resected early stage pure invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation. <i>Breast</i> , 2017 , 35, 21-26	3.6	12
101	Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience. <i>Breast Cancer Research and Treatment</i> , 2017 , 168, 507-514	4.4	7
100	Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017 , 36, 143	12.8	1
99	A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017 , 232, 1571-1578	7.1578	12
98	Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?. <i>Future Oncology</i> , 2017 , 13, 2791-2797	3.6	19
97	Temozolomide low-dose chemotherapy in newly diagnosed low-grade gliomas: activity, safety, and long-term follow-up. <i>Tumori</i> , 2017 , 103, 255-260	1.7	4
96	Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study. <i>Oncotarget</i> , 2017 , 8, 55575-55581	3.3	9
95	Efficacy and safety of T-DM1 in the common-practice of HER2+ advanced breast cancer setting: a multicenter study. <i>Oncotarget</i> , 2017 , 8, 64481-64489	3.3	15
94	Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their levels correlate with breast cancer cell proliferation. <i>Onc Immunology</i> , 2016 , 5, e1074375	7.2	13
93	Spine Surgery in Patients with Metastatic Breast Cancer: A Retrospective Analysis. <i>World Neurosurgery</i> , 2016 , 90, 133-146	2.1	6
92	Real-life effectiveness of T-DM1 in heavily pretreated HER2-positive advanced breast cancer patients: An Italian observational study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e12019-e12019	2.2	1
91	Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases. <i>Translational Lung Cancer Research</i> , 2016 , 5, 637-646	4.4	4
90	Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study. <i>PLoS ONE</i> , 2016 , 11, e0156221	3.7	2
89	First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016 , 35, 104	12.8	29
88	Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival. <i>Breast</i> , 2016 , 29, 24-30	3.6	8
87	AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016 , 18, 1304-12	1	53

86	Searching for Evidence to Support the Use of Ginger in the Prevention of Chemotherapy-Induced Nausea and Vomiting. <i>Journal of Alternative and Complementary Medicine</i> , 2016 , 22, 486-8	2.4	7
85	CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1564-73	2.2	163
84	Cognitive rehabilitation training in patients with brain tumor-related epilepsy and cognitive deficits: a pilot study. <i>Journal of Neuro-Oncology</i> , 2015 , 125, 419-26	4.8	34
83	Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas. <i>Neuroradiology</i> , 2015 , 57, 1269-80	3.2	32
82	Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology). <i>Journal of Neuro-Oncology</i> , 2015 , 125, 359-67	4.8	34
81	Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 6177-83	4.4	16
80	The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. <i>PLoS ONE</i> , 2015 , 10, e0136731	3.7	7
79	The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma. <i>Disease Markers</i> , 2015 , 2015, 604719	3.2	10
78	Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice. <i>Future Oncology</i> , 2015 , 11, 431-8	3.6	15
77	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , 2015 , 6, 42773-80 ³	3.3	13
76	Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic. <i>Journal of Molecular Medicine</i> , 2014 , 92, 681-95	5.5	13
75	Weight of epilepsy in brain tumor patients. <i>Journal of Neuro-Oncology</i> , 2014 , 118, 385-393	4.8	27
74	Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study. <i>Journal of Cancer</i> , 2014 , 5, 320-7	4.5	47
73	Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial. <i>Tumori</i> , 2014 , 100, 432-8	1.7	2
72	Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. <i>BMC Cancer</i> , 2013 , 13, 164	4.8	16
71	Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 699-706	4	15
70	Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease. <i>Journal of Neuro-Oncology</i> , 2013 , 113, 313-25	4.8	57
69	An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 629-41	4	9

68	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. <i>ClinicoEconomics and Outcomes Research</i> , 2013 , 5, 125-35	1.7	19
67	Leptomeningeal carcinomatosis in aggressive germ non-seminoma testicular tumor: a case report and review of literature. <i>Clinical Neurology and Neurosurgery</i> , 2012 , 114, 1081-5	2	2
66	Perfusion Computed Tomography (PCT) adopting different perfusion metrics: recurrence of brain metastasis or radiation necrosis?. <i>European Journal of Radiology</i> , 2012 , 81, 1246-52	4.7	10
65	Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. <i>BMC Cancer</i> , 2012 , 12, 482	4.8	18
64	Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012 , 31, 33	12.8	22
63	Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. <i>Epileptic Disorders</i> , 2012 , 14, 388-97	1.9	19
62	Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. <i>Journal of Neuro-Oncology</i> , 2011 , 104, 205-14	4.8	77
61	Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. <i>Supportive Care in Cancer</i> , 2011 , 19, 697-701	3.9	15
60	Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. <i>Supportive Care in Cancer</i> , 2011 , 19, 1217-25	3.9	83
59	Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 67, 687-93	3.5	8
58	Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011 , 30, 10	12.8	68
57	Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2011 , 30, 54	12.8	28
56	HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. <i>Clinical Cancer Research</i> , 2011 , 17, 2055-64	12.9	79
55	Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2834-5; author reply 2835	2.2	5
54	Glioblastoma Patients: Role of Methylated MGMT 2011 , 73-79		
53	Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease. <i>Journal of Clinical Oncology</i> , 2010 , 28, e337; author reply e338-9	2.2	7
52	Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. <i>Oncology</i> , 2010 , 78, 141-9	3.6	25
51	Supportive care in neurooncology. <i>Current Opinion in Oncology</i> , 2010 , 22, 621-6	4.2	38

50	Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 391-7	3.5	23
49	Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study. <i>Journal of Neuro-Oncology</i> , 2010 , 100, 209-15	4.8	13
48	Time to first tumor progression as outcome predictor of a second trastuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer. <i>Breast Journal</i> , 2010 , 16, 66-72	1.2	8
47	Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation. <i>BMC Cancer</i> , 2009 , 9, 101	4.8	24
46	Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. <i>Neurological Sciences</i> , 2009 , 30, 353-9	3.5	37
45	The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009 , 28, 60	12.8	44
44	Quantitative analysis of CT-perfusion parameters in the evaluation of brain gliomas and metastases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009 , 28, 38	12.8	12
43	Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. <i>Anticancer Research</i> , 2009 , 29, 2607-10	2.3	23
42	Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. <i>Breast</i> , 2008 , 17, 499-505	3.6	43
41	A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. <i>Breast Cancer Research</i> , 2008 , 10, R74	8.3	77
40	HER-2-positive metastatic breast cancer: trastuzumab and beyond. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 2583-601	4	35
39	Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1619-25	2.2	131
38	Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study. <i>Journal of Neuro-Oncology</i> , 2008 , 87, 79-84	4.8	12
37	Metastases to the cerebellum. Results and prognostic factors in a consecutive series of 44 operated patients. <i>Journal of Neuro-Oncology</i> , 2008 , 88, 331-7	4.8	18
36	Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. <i>Journal of Neuro-Oncology</i> , 2008 , 90, 217-24	4.8	20
35	Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 717-25	3.5	35
34	Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. <i>Supportive Care in Cancer</i> , 2008 , 16, 1375-80	3.9	10
33	Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas. <i>PLoS ONE</i> , 2008 , 3, e1592	3.7	45

32	Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule. <i>Anticancer Research</i> , 2008 , 28, 1245-58	2.3	8
31	Aromatase inhibitors in post-menopausal metastatic breast carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2007 , 16, 1023-36	5.9	3
30	Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. <i>Oncologist</i> , 2007 , 12, 1467-9; author reply 1469-71	5.7	29
29	Zoledronic acid and angiogenesis. <i>Clinical Cancer Research</i> , 2007 , 13, 6850; author reply 6850-1	12.9	5
28	HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. <i>Current Opinion in Obstetrics and Gynecology</i> , 2007 , 19, 56-62	2.4	76
27	Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism. <i>Thrombosis Research</i> , 2007 , 119, 525-9	8.2	2
26	Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. <i>Bone</i> , 2007 , 41, 155-6	4.7	5
25	Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients. <i>Cancer Investigation</i> , 2007 , 25, 102-5	2.1	31
24	Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 57, 615-23	3.5	20
23	Chemotherapy in neoplastic meningitis. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 60, 194-200	7	19
22	Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?. <i>Breast</i> , 2006 , 15, 269-72	3.6	2
21	What is the biological significance of circulating blood levels of metalloproteinases?. <i>Clinical Cancer Research</i> , 2006 , 12, 3550-1; author reply 3551	12.9	2
20	Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer. <i>Oncologist</i> , 2006 , 11, 533; author reply 534	5.7	0
19	Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer. <i>Oncologist</i> , 2006 , 11, 853-4	5.7	8
18	Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?. <i>Journal of Clinical Oncology</i> , 2006 , 24, e60-1	2.2	19
17	Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients. <i>Cancer Treatment Reviews</i> , 2006 , 32, 325-32	14.4	15
16	Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?. <i>Chest</i> , 2006 , 130, 1808-16	5.3	30
15	Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. <i>Oncology</i> , 2005 , 69, 35-43	3.6	107

14	New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials. <i>Cancer</i> , 2005 , 104, 1335-42	6.4	32
13	Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005 , 90, 319	4.4	2
12	Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7248-50; author reply 7250	2.2	11
11	Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6908-18	2.2	79
10	HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?. <i>Journal of Clinical Oncology</i> , 2004 , 22, 568-9	2.2	5
9	Effect of filgrastim on serum lactate dehydrogenase and alkaline phosphatase values in early breast cancer patients. <i>Cancer Investigation</i> , 2004 , 22, 650-3	2.1	4
8	Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3462-8	2.2	61
7	Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. <i>Cancer</i> , 2003 , 98, 337-43	6.4	44
6	Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003 , 86, 107-9	5.1	9
5	Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. <i>Drugs of Today</i> , 2003 , 39, 157-74		109
4	Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 48, 255-8	3.5	2
3	Weekly schedule of vinorelbine in pretreated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2000 , 59, 223-9	4.4	19
2	Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 45, 513-5	3.5	4
1	Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal women. <i>Breast Cancer Research and Treatment</i> , 1999 , 55, 259-66	4.4	12